NCT06511778View on ClinicalTrials.gov

sTErnAl heMostasiS Trial

PHASE4RecruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

October 17, 2024

Primary Completion Date

August 31, 2026

Study Completion Date

September 30, 2026

Conditions
Excessive Bleeding During Surgery
Interventions
DRUG

Hemoblast Bellows application

Hemoblast bellows is a hemostatic agent clinically proven effective on the validated SPOT GRADE scale for minimal, mild, and moderate bleeding. Patients will have the Hemoblast bellows applied during on pump sternotomy surgery.

Trial Locations (1)

27610

RECRUITING

WakeMed Health and Hospitals, Raleigh

Sponsors

Collaborators (1)

Dilon Technologies
All Listed Sponsors
collaborator

Dilon Technologies

UNKNOWN

lead

WakeMed Health and Hospitals

OTHER